## **ICMJE DISCLOSURE FORM**

Date:			5/17/2022				
Your Name:			Dr. Wouter Vogel				
Manuscript Title:			Lutetium-177-PSMA bij castratie resistent prostaatcarcinoom				
Manuscript Number (if known):			NA				
In the interest of transparency, we content of your manuscript. "Rela affected by the content of the maindicate a bias. If you are in doubt The author's relationships/activitic epidemiology of hypertension, you that medication is not mentioned			rt for the work reported in this manuscript without time limit. For all other items, the time				
			l entities with whom you have this ship or indicate none (add rows as needed	Specifications/Comments (e.g., if payments were made to you or to your institution)			
			Time frame: Since the initial planning	g of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	⊠ No	one	Click the tab key to add additional rows.			
Time frame: past 36 months							
2	Grants or contracts from any entity (if not indicated in item #1 above).	prospe	ne ed an unrestricted research grant for ctive study with Lutetium-177-PSMA-617 riple-A / Novartis.				
3	Royalties or licenses	⊠ No	one				

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	None     Non	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)			
11	Stock or stock options	None     Non				
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	□ None  Receiving Lutetium-177-PSMA-617 free of charge from Triple-A / Novartis in the scope of the abovementioned unrestricted research grant.				
13	Other financial or non-financial interests	None     ■				
Please place an "X" next to the following statement to indicate your agreement:   I certify that I have answered every question and have not altered the wording of any of the questions on this form.						